Introduction
Cytochromes P450 (CYPs) are hemoproteins involved in the metabolism of some endogenous compounds (estradiol, fatty acids) and numerous xenobiotics.
CYPs are the main enzymes involved in the bioactivation of environmental procarcinogens. CYP1A1 catalyzes the bioactivation of polycyclic aromatic hydrocarbons (PAHs) and arylamines. PAHs are ubiquitous compounds found in tobacco smoke, industrial workplace, and food. Arylamines are pyrolysis derivatives of proteins. PAHs and arylamines are mainly involved in the etiology of smokers' lung cancers and colorectal cancers, respectively (1, 2) . Moreover, CYP1A1 overexpression was associated with predisposition to various human cancers (3) .
CYP1A1 is constitutively expressed in human enterocytes at relatively low level. However, it should be borne in mind that its expression is highly enhanced after exposition to chemical inducers, modulating cellular susceptibility to procarcinogens.
CYP1A1 gene expression is mainly regulated by the Aryl hydrocarbon
Receptor (AhR) which is activated by a variety of xenobiotic compounds including dioxins, PAHs (4-6), flavonoids, indole and benzimidazole derivatives (7) (8) (9) . The AhR is present in cytoplasm as an inactive form associated with two hsp90 and another protein, named AIP, involved in the stability of the complex AhR-hsp90. The ligand binding on AhR induces the dissociation of this complex and activates the receptor.
After its activation, AhR is able to translocate in the nucleus, where it dimerizes with its partner, the aryl hydrocarbon receptor nuclear translocator (Arnt). This new complex binds specifically to enhancer DNA sequences within the CYP1A1 promoter called XRE (Xenobiotic Responsive Element).
In spite of the fact that AhR plays a central role in CYP1A1 gene regulation, the activation of this transcription factor cannot always explain the observed CYP1A1 induction. For instance, carbaryl which is not an AhR ligand was found to induce CYP1A1 (10) by a mechanism not yet characterized.
AhR excepted, the other transcription factor involved in CYP1A1 induction was RAR but the level of induction reached was relatively faint (11) .
It has been previously demonstrated that induction of CYP1A1 activity can be obtained by cell culture agitation, with a level comparable to those obtained with exposure to 0.1 nM TCDD (2,3,7,8-tetrachlorodibenzo-p-dioxine) (12) . Increasing shear stress leads to an increase of arachidonic acid level (13, 14) and arachidonic acid metabolites are PPAR ligands (15) Moreover, it was demonstrated that peroxisome proliferators, such as phthalates, can increase the DNA adducts induced by the bioactivation of benzo(a)pyrene which is mainly catalyzed by CYP1A1 (16) . The mechanism involved in this increase of DNA adducts was not characterized. So, phthalates appeared to be inducers of CYP1A1 activity. To date, it has been demonstrated that some phthalate derivatives are potent agonist ligands of PPAR and to a lesser extent of PPAR. We hypothesized that the potentiation of benzo(a)pyrene DNA adducts by phthalates could be related to CYP1A1 induction via the PPAR pathway. Three independent experiments were at least realized in triplicate. Three independent experiments were at least realized in triplicate.
EROD activity
Site-Directed mutagenesis of the CYP1A1 promoter The PPRE mutations of pRNH25c were introduced using the QuickChange site-directed mutagenesis kit (Stratagene, France) to obtain the pRNH25c(PPRE1), the pRNH25c(PPRE2) and the pRNH25c(PPRE1+2). The primers sense and antisense were used for mutagenesis. The primers sens were as follows (the PPRE core was underlined and bold letters represent mutated nucleotides compared to the wild type sequence (Wt)):
Presence of the mutations was verified by DNA sequencing. Cells were transfected by either the pRNH25c or pRNH25c(PPRE1) or pRNH25c(PPRE2) or pRNH25c(PPRE1+2) and after a 48 h-treatment with WY-14643 (200 µM) the CAT expression was evaluated as described above.
In vitro translation and electromobility shift assays Electromobility shift assays were performed using PPAR and RXR prepared by in vitro translation using a Statistical analysis Statistical analysis were performed using the Newman-Keuls test. Data were considered statistically significant at a p<0.05. Significant results were noted with * or ** or *** for a p<0.05, p<0.01 and p< 0.001 respectively.
Results

Induction of CYP1A1 gene by PPAR ligands
CaCo The mutation of one of the two CYP1A1 PPRE sites led to a decrease of CYP1A1
promoter activation by WY-14643. Indeed, the induction of CAT expression was lower using the pRNH25cPPRE1 or pRNH25cPPRE2 constructs (1.6-fold and 1.4-fold respectively) as compared to the pRNH25c construct (2.4-fold). When the two sites were mutated (pRNH25cPPRE1+2) the decrease of WY-14643 effect was higher (1.1-fold at 200 µM WY-14643).
The two CYP1A1 PPRE sites were able to bind PPAR
We first checked the binding of an in vitro translated PPAR-RXR heterodimer to the two CYP1A1 putative PPRE sequences by gel shift assay (Fig. 5) . As expected, a specific retarded band was observed when PPAR and its partner RXR were incubated together with the target oligonucleotide (lane 5 and 11), but not when these receptors were incubated separately (lanes 3, 4 and 9, 10). We confirmed that the shift obtained using the CYP1A1 PPRE1 and PPRE2 was the consequence of the binding of PPAR usinga specific PPAR antibody which produced a super shift shown in lanes 6 and 12.
In addition, the specific PPAR/RXR-PPRE complex was repressed in a dose-dependant manner when incubated in the presence of 10-fold ( Fig. 6 lanes 7, 9, 11) or 50-fold (lanes 6, 8, 10) excess of unlabeled consensus PPRE or unlabelled CYP1A1-PPRE1 or CYP1A1-PPRE2 sequences.
In the same conditions, a 50-fold excess of mutated PPRE1 or PPRE2
CYP1A1 sequences did not affect the binding of PPAR/RXR on the PPRE consensus core (Fig 6 lanes 12 and 13 respectively) . A supershifted band appeared using a PPAR antibody (lane 14).
These observations showed that the in vitro translated heterodimer PPAR/RXR binds to the two PPRE1 and PPRE2 sites within the CYP1A1 gene promoter.
To strengthen our demonstration, ChIP analysis was performed using CaCo-2 cells untreated or treated with 200 µM WY-14643 for 1 h. We showed (Figure 7 ) that the PPARRXR heterodimer binds to the PPRE sites located within the proximal CYP1A1 gene promoter.
Discussion
We Since CYP1A1 is mainly regulated by the Ah receptor, it was logical to assume that WY-14643 could have a direct or indirect action on this transcription factor.
However, using XRE-TK-CAT construct we showed that WY-14643 failed to activate XRE site, demonstrating that CYP1A1 induction by PPAR ligand did not involve AhR.
Sequence analysis of CYP1A1 promoter revealed the presence of two putative PPRE sites. Indeed, treatment with WY-14643 increased CAT expression when cells were transiently transfected with pRNH25c harboring the wild-type CYP1A1
promoter. The results obtained in Fig. 4 clearly demonstrate that the mutation of one PPRE site (PPRE1 or PPRE2) reduces the CAT induction while no induction occurred with pRNH25c (PPRE1+2). So, it appears that the two PPRE sites located within the promoter at positions -931/-919 (CYP1A1 PPRE1) and -531/-519 (CYP1A1 PPRE2) respectively were necessary for the CYP1A1 induction by PPAR ligands.
The direct role played by these 2 PPRE sites in the binding of PPAR transcription factor was evaluated first by EMSA. We found that even if the two sites diverge from the canonical DR1 sequence they are still able to bind PPAR with good efficiency . PPAR binding is no longer possible when mutations are introduced in these CYP1A1 PPRE sites. In order to demonstrate the in vivo relevance of these PPRE sites, we performed ChIP assays. We immunoprecipitated the human To date, it has not been clearly documented whether, without any ligand the PPARRXRheterodimer is unbound or bound to PPRE sites in an inactive conformation as has been largely described for RAR (26) . It seems that the binding of PPARRXR on PPRE sites in the presence or absence of PPAR ligands is dependent on the nature of the tissue, the cell type and the gene studied.
The PPRE2 site appears to have an inverted orientation compared to a canonical consensus site while PPRE1 site displays a conventional orientation.
Sequence alignment of CYP1A1 promoter (Figure 8 ) from various species demonstrates that PPRE1 and PPRE2 sites are highly conserved in human, rat and mouse species. Rat and mouse harbor the same PPRE1 and PPRE2 sequences and differ from humans in that they exhibit a unique base transition. Interestingly, the flanking regions are also conserved. Moreover, when sequence alignment was performed with CYP1A1 promoter from fish species, such as Anguilla japonica or
Microgadus tomcod, we were unable to localize any PPRE sites, while several XRE sites are located within these promoters (data not shown). PPAR orthologs have already been described in fish species. Therefore the CYP1A1 regulation by PPAR occurred tardily in the evolution of species, contrary to the regulation of CYP1A1 by AhR.
Until now, only the CYP4A, involved in fatty acid biotransformation, was known to be induced by PPAR ligands within the CYPs superfamily, (27) . Since CYP1A1, largely concerned in procarcinogens activation, is also implicated in fatty acid metabolism (28) , it was logical to find its expression regulated through PPAR.
Moreover, CYP1A1 modification level could have a physiological impact in terms of fatty acid metabolite levels.
Until now, CYP1A1 was known to be expressed and induced by the transcription factor AhR. This is the first time that another strong CYP1A1 induction pathway, apart from AhR, has been described. We demonstrated that CYP1A1 was highly induced by PPAR via two PPRE sites within the promoter. The upregulation of CYP1A1 by PPAR ligands may be involved in human carcinogenesis, notably in colon through an increase of CYP1A1-bioactivated procancerogens present in diet, such as arylamines. 
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